Title : Clinical pharmacology of marijuana: Update 2024
Abstract:
Over the past decade, marijuana use throughout the world has increased including within the United States where it remains a federally-banned substance. According to a 2024 Newsweek Report, cannabis sales worldwide may be approximately $61 billion this year, and much higher by 2028.
Many conditions are being self-treated with marijuana including anxiety, posttraumatic stress disorder, and chronic pain. In regard to the latter condition, advanced clinical research is needed to document such applications. In an ongoing pilot study led by Dr. Goldstein, daily oral doses of a defined dose combination of THC-CBD combination over a four-week period have been shown to reduce pain scores and use of other analgesic medications in patients with chronic neuropathic pain; these data will be shown. In addition, other topics to be presented are clinical pharmacological aspects of THC: endogenous cannabinoid receptor system, mechanisms of action, adverse effects, addiction liability, physical dependence, withdrawal reactions and drug interactions.
